Funding the science that could change everything.
There's no approved cure for L-CMD yet. Researchers are making real progress in the lab, and we want to help that progress reach children like Archie.
Where research is heading
Here's a quick, plain-language look at some of the approaches scientists are exploring. Most of this work is still in early, preclinical stages.
Gene editing
Scientists are testing CRISPR-based tools in lab models to correct or switch off the faulty copy of LMNA. Early mouse studies have shown longer survival and better heart function.
PreclinicalBase editing
A precise "spell-check" for DNA. In 2025, researchers used base editors carried by a virus to correct two LMNA variants in mice, including one that causes congenital muscular dystrophy, in the same short stretch of the gene where many L-CMD changes cluster. Lifespan and heart function both improved.
PreclinicalSilencing the faulty copy
L-CMD is caused by one altered copy of LMNA interfering with the healthy one. Rather than correcting it, some researchers are switching it off and leaving the good copy to work alone. In mice carrying an L-CMD variant, this extended survival by about a quarter and improved heart function.
PreclinicalNew delivery methods
Getting therapies into muscle and heart cells is a major hurdle. Non-viral delivery systems are being developed to carry gene-editing tools where they need to go.
PreclinicalNatural history and registries
Understanding how L-CMD progresses over time is essential for designing clinical trials, and many individual variants have never been described in the medical literature at all. Family participation in studies and registries is what turns scattered cases into knowledge researchers can use — and it's something families can do today.
OngoingLearn more: Base editing in LMNA mouse models (PNAS, 2025) · Allele-specific CRISPR in L-CMD mice (2025) · Cure CMD research · L-CMD Research Foundation · ClinicalTrials.gov
Prime editing: a search-and-replace for DNA
Nearly every child with L-CMD has one small change in the LMNA gene, and it usually appears for the first time in that child. Prime editing is a newer tool built to rewrite exactly that kind of change.
How it works
Introduced in 2019, prime editing pairs a guide that finds the exact spot in the DNA with a small copier that writes the corrected letters in place. It nicks a single strand instead of cutting the DNA in two, and it can make any letter swap as well as put back missing letters.
Why it matters for L-CMD
Base editing, the approach used in most LMNA studies so far, is limited in which changes it can undo. It cannot restore letters that are missing, and it cannot make every kind of letter swap. For the L-CMD changes that fall outside what base editing reaches, prime editing is the tool designed to put the original letter back.
Where it stands today
Prime editing reached patients for the first time in 2025, in a small trial for a rare immune disorder, with encouraging early results. For L-CMD it is still laboratory work: there is no prime editing treatment and no trial yet. Newer base editors able to make the harder letter swaps have been published since 2023, but they are earlier still.
What has to happen next
The hardest part is delivery: getting the editing tools into muscle and the heart throughout the body. Researchers are testing split delivery and non-viral particles that can be given more than once. Each genetic change also needs its own custom guide, so therapies may be built family by family.
Sources: Anzalone et al., Nature (2019) · First-in-human prime editing, NEJM (2025) · Ben Yaou et al., Brain Communications (2021) · Base editing in LMNA mouse models, PNAS (2025)
How we'll invest in research
Fund what's promising
We'll direct funds to scientific work with a real path toward treatments for L-CMD.
Work together
We plan to partner with established researchers and rare disease organizations instead of duplicating their work.
Report openly
We'll share where donations go and what they help accomplish.
Are you an L-CMD researcher?
We'd love to learn about your work and explore how we can help.